<DOC>
	<DOC>NCT01420562</DOC>
	<brief_summary>The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough levels of posaconazole reached in patients with different stages of mucositis, due to chemotherapy and total body irradiation.</brief_summary>
	<brief_title>Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Patients receiving allogeneic stem cell transplantation Treated with prophylactic posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily) to prevent invasive fungal infections Gastroparesis Vomiting or diarrhea within 2 hours after intake of posaconazole Concomitant administration of potent inducers of the enzyme UGT1A4: carbamazepine,phenytoin, phenobarbital, rifabutin, rifampicin,... Age under 18 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>allogeneic HSCT</keyword>
	<keyword>posaconazole</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>mucositis</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>